Inventor · disambiguated record
Marco L. Davila
Also filed as: DAVILA MARCO · DAVILA MARCO L
13 granted patents·38 pending applications·11 citations·filing 2017–2025
85Inventor score
Files withH LEE MOFFITT CANCER CT & RES47UNIV MINNESOTA2H LEE MOFFITT CANCER CENTER AND RES INSTITURE INC1ROSWELL PARK CANCER INST CORPORATION1
Top patents by PatentIndex Score
51 records- 0183US11479606B2Compositions and methods for targeting CD33-expressing cancersH LEE MOFFITT CANCER CT & RES·Filed 2018·Granted Oct 25, 2022·2 cites·11 claims
- 0281US11434290B2Chimeric antigen receptors with enhanced NFκB signalingH LEE MOFFITT CANCER CT & RES·Filed 2018·Granted Sep 6, 2022·2 cites·18 claims
- 0380US12065474B2Chimeric antigen receptors with mutated CD28 costimulatory domainsH LEE MOFFITT CANCER CT & RES·Filed 2018·Granted Aug 20, 2024·1 cites·10 claims
- 0480US12036273B2Compositions and methods for targeting CD99-expressing cancersH LEE MOFFITT CANCER CT & RES·Filed 2019·Granted Jul 16, 2024·1 cites·17 claims
- 0580US11525004B2Recombinant CD123-binding antibodiesH LEE MOFFITT CANCER CT & RES·Filed 2018·Granted Dec 13, 2022·2 cites·11 claims
- 0679US2024376201A1Compositions and methods for targeting cd33-expressing cancersH LEE MOFFITT CANCER CT & RES·Filed 2024·Application pending·0 cites
- 0778US12036242B2CAR T cells that target B-cell antigensH LEE MOFFITT CANCER CT & RES·Filed 2019·Granted Jul 16, 2024·1 cites·6 claims
- 0878US11951129B2Compositions and methods for targeting CLEC12A-expressing cancersH LEE MOFFITT CANCER CT & RES·Filed 2019·Granted Apr 9, 2024·1 cites·12 claims
- 0977US12492254B2CD83-binding chimeric antigen receptorsH LEE MOFFITT CANCER CT & RES·Filed 2019·Granted Dec 9, 2025·1 cites·15 claims
- 1075US12037394B2Compositions and methods for targeting CD33-expressing cancersH LEE MOFFITT CANCER CT & RES·Filed 2022·Granted Jul 16, 2024·0 cites·5 claims
- 1175US2025136700A1Bispecific antibody for cancer immunotherapyH LEE MOFFITT CANCER CT & RES·Filed 2024·Application pending·0 cites
- 1274US2024299519A1Compositions and methods for targeting cd99-expressing cancersH LEE MOFFITT CANCER CT & RES·Filed 2024·Application pending·0 cites
- 1371US2025388860A1Artificial antigen presenting cells comprising protein l for expanding immune cells for immunotherapyH LEE MOFFITT CANCER CT & RES·Filed 2025·Application pending·0 cites
- 1469US2024197779A1Anti-cd83 chimeric antigen receptor expressing t regulatory cellsH LEE MOFFITT CANCER CT & RES·Filed 2023·Application pending·0 cites
- 1569US2023250151A1Artificial antigen presenting cells for genetic engineering of immune cellsH LEE MOFFITT CANCER CT & RES·Filed 2022·Application pending·0 cites
- 1669US2024299456A1Car t cells that target b-cell antigensH LEE MOFFITT CANCER CT & RES·Filed 2024·Application pending·0 cites
- 1767US2025302878A1Nkg2d expressing car-t cellsH LEE MOFFITT CANCER CT & RES·Filed 2023·Application pending·0 cites
- 1864US2025025503A1Chimeric antigen receptors with mutated dap10 costimulatory domainsH LEE MOFFITT CANCER CT & RES·Filed 2022·Application pending·0 cites
- 1961US2021230543A1Artificial antigen presenting cells comprising protein l for expanding immune cells for immunotherapyH LEE MOFFITT CANCER CT & RES·Filed 2019·Application pending·0 cites
- 2060US12077590B2Bispecific antibody for cancer immunotherapyH LEE MOFFITT CANCER CT & RES·Filed 2018·Granted Sep 3, 2024·0 cites·11 claims
- 2160US2023265184A1Chimeric antigen receptors with enhanced nfkb signalingH LEE MOFFITT CANCER CT & RES·Filed 2022·Application pending·0 cites
- 2259US2025241952A1Cd83 dual car t cellsH LEE MOFFITT CANCER CT & RES·Filed 2023·Application pending·0 cites
- 2359US2024307335A1IRG Blockade to Armor CAR T Cells Against Myeloid DysfunctionROSWELL PARK CANCER INST CORPORATION·Filed 2024·Application pending·0 cites
- 2459US2024252636A1Dual egfr-muci chimeric cantigen receptor t cellsH LEE MOFFITT CANCER CT & RES·Filed 2022·Application pending·0 cites
- 2558US11524988B2Artificial antigen presenting cells for genetic engineering of immune cellsH LEE MOFFITT CANCER CT & RES·Filed 2017·Granted Dec 13, 2022·0 cites·17 claims
- 2658US2024226294A9Customized chimeric antigen receptor polypeptidesH LEE MOFFITT CANCER CT & RES·Filed 2022·Application pending·0 cites
- 2758US2024139322A1Compositions and methods to reduce therapeutic t cell toxicityH LEE MOFFITT CANCER CT & RES·Filed 2022·Application pending·0 cites
- 2857US2022235114A1Chimeric antigen receptors with mutated cd28 costimulatory domainsH LEE MOFFITT CANCER CT & RES·Filed 2022·Application pending·0 cites
- 2957US2024091356A1Bi-specific car t ccells for b cell malignanciesH LEE MOFFITT CANCER CT & RES·Filed 2022·Application pending·0 cites
- 3057US2025052748A1Cd83 and allo- and autoimmune conditionsUNIV MINNESOTA·Filed 2022·Application pending·0 cites
- 3156US2020108098A1Anti-cd83 chimeric antigen receptor expressing t regulatory cellsH LEE MOFFITT CANCER CT & RES·Filed 2019·Application pending·0 cites
- 3256US2024269284A1Methods of using anti-cd83 chimeric antigen receptor expressing t cellsH LEE MOFFITT CANCER CT & RES·Filed 2022·Application pending·0 cites
- 3354US2025003954A1Universal til cytotoxicity assayH LEE MOFFITT CANCER CT & RES·Filed 2022·Application pending·0 cites
- 3454US2024173411A1Methods for treating cd83-expressing cancerH LEE MOFFITT CANCER CT & RES·Filed 2022·Application pending·0 cites
- 3554US2023203168A1Dual EGFR-MUC1 Chimeric Antigen Receptor T CellsH LEE MOFFITT CANCER CT & RES·Filed 2021·Application pending·0 cites
- 3654US2023257477A1Dual chimeric antigen receptor t cells targeting ccd99- and clec12a-expressing cancersH LEE MOFFITT CANCER CT & RES·Filed 2021·Application pending·0 cites
- 3753US2023039099A1Akt inhibitors for enhancing chimeric t cell persistenceH LEE MOFFITT CANCER CT & RES·Filed 2020·Application pending·0 cites
- 3852US2023051885A1Systems and Methods for Producing Efficacious Regulatory T CellsH LEE MOFFITT CANCER CT & RES·Filed 2020·Application pending·0 cites
- 3952US2023321239A1Chimeric antigen receptor t cells for treating autoimmunityH LEE MOFFITT CANCER CT & RES·Filed 2021·Application pending·0 cites
- 4051US2022289862A1Anti-cd83 chimeric antigen receptor expressing t regulatory cellsH LEE MOFFITT CANCER CT & RES·Filed 2020·Application pending·0 cites
- 4151US2021236547A1Rapid production, expansion, and increased purity of car-t cells using beads with protein lH LEE MOFFITT CANCER CT & RES·Filed 2019·Application pending·0 cites
- 4250US2021024608A1Nkg2d chimeric antigen receptorsH LEE MOFFITT CANCER CT & RES·Filed 2019·Application pending·0 cites
- 4350US2023390391A1Bi-specific chimeric antigen receptor t cells targeting cd83 and interleukin 6 receptorUNIV MINNESOTA·Filed 2021·Application pending·0 cites
- 4450US2022228114A1THERAPEUTIC T-CELLS WITH MODIFIED EXPRESSION OF T-BET, EOMES, AND c-MYB TRANSCRIPTION FACTORSH LEE MOFFITT CANCER CT & RES·Filed 2020·Application pending·0 cites
- 4550US2022154144A1Artificial antigen presenting cells comprising ligands for nkg2d for expanding immune cells for immunotherapyH LEE MOFFITT CANCER CT & RES·Filed 2020·Application pending·0 cites
- 4650US2022241332A1Therapeutic b-cells engineered to express bispecific t cell engager antibodiesH LEE MOFFITT CANCER CT & RES·Filed 2020·Application pending·0 cites
- 4748US11976121B2CD123-binding chimeric antigen receptorsH LEE MOFFITT CANCER CT & RES·Filed 2018·Granted May 7, 2024·0 cites·18 claims
- 4848US2022289813A1Chimeric antigen receptors for treating myeloid malignanciesH LEE MOFFITT CANCER CT & RES·Filed 2020·Application pending·0 cites
- 4947US11458169B2TIM3-binding chimeric antigen receptorsH LEE MOFFITT CANCER CT & RES·Filed 2018·Granted Oct 4, 2022·0 cites·12 claims
- 5047US2020333329A1Targeted cytokine blockades for car-t therapyH LEE MOFFITT CANCER CT & RES·Filed 2018·Application pending·0 cites
Showing the top 50 of 51 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Marco L. Davila files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →